课题基金 / 基金详情

Targeting atypical B7 family checkpoints in poor-outcome triple-negative breast cancers

Targeting atypical B7 family checkpoints in poor-outcome triple-negative breast cancers
针对预后不良的三阴性乳腺癌的非典型 B7 家族检查点
批准号:
490501
负责人:
Sleiman Hanadi
金额:
$76.63万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
未结题
起止时间:
2023-09-01 至 2028-09-01

项目摘要

项目成果

Sleiman Hanadi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Triple-negative breast cancer (TNBC), accounting for 15 to 20% of all breast cancers, is associated with earlier age onset, therapeutic resistance, metastasis, and lower survival rates. Immunotherapy, in which the patient's immune system is reprogrammed t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DNA Cages as a Platform for Efficient and Selective Delivery of Therapeutics into Tumor Cells
海外基金